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Introduction
CaV1.2, an L-type voltage–gated Ca
2+ channel, plays essential roles in many excitable cells, including 
neurons, smooth and cardiac muscle cells, and endocrine cells (1). Upon membrane depolarization, Ca2+ 
influx through the activated CaV1.2 channel triggers a wide range of  physiological processes, such as exci-
tation-contraction coupling in cardiac muscle cells, graded contraction in smooth muscle cells of  the vas-
culature and gut, hormone secretion in endocrine tissue, postsynaptic responses in various neurons, and 
activation of  gene expression paradigms across a variety of  tissues. Common to all of  these examples is 
that the excitable cells in which they occur support frequent and dynamic changes in membrane potential 
that facilitate activation of  the voltage-gated CaV1.2 channel. In contrast, roles for CaV1.2 signaling in non-
excitable cells are not well understood, but a gain-of-function mutation (G406R) in the human CACNA1C 
gene, encoding the pore-forming α1C subunit of  CaV1.2, causes Timothy syndrome (TS) (2) and reveals 
prominent but previously unappreciated roles for CaV1.2 in nonexcitable tissue (3).
TS is a multisystem disorder marked by life-threatening cardiac arrhythmias and soft-tissue syndactyly. 
The G406R mutation in CaV1.2 that causes TS reduces voltage-dependent inactivation, thus impairing 
channel closure and allowing more Ca2+ influx into the cell. This increased Ca2+ entry, and consequent 
delay of  membrane repolarization, provides a clear rationale for the cardiac arrhythmias. How CaV1.2 par-
ticipates in limb development and specifically why the mutant channel causes syndactyly, however, are not 
known. Some other variably penetrant features of  TS, such as craniofacial and dental abnormalities and 
delayed hair development, demonstrate that a broad array of  tissues are affected by aberrant Ca2+ influx 
through CaV1.2 and reveal other unexpected but critical roles of  CaV1.2 in nonexcitable tissues.
While the prevalence of osteoporosis is growing rapidly with population aging, therapeutic options 
remain limited. Here, we identify potentially novel roles for CaV1.2 L-type voltage–gated Ca
2+ 
channels in osteogenesis and exploit a transgenic gain-of-function mutant CaV1.2 to stem bone 
loss in ovariectomized female mice. We show that endogenous CaV1.2 is expressed in developing 
bone within proliferating chondrocytes and osteoblasts. Using primary BM stromal cell (BMSC) 
cultures, we found that Ca2+ influx through CaV1.2 activates osteogenic transcriptional programs and 
promotes mineralization. We used Prx1-, Col2a1-, or Col1a1-Cre drivers to express an inactivation-
deficient CaV1.2 mutant in chondrogenic and/or osteogenic precursors in vivo and found that the 
resulting increased Ca2+ influx markedly thickened bone not only by promoting osteogenesis, but 
also by inhibiting osteoclast activity through increased osteoprotegerin secretion from osteoblasts. 
Activating the CaV1.2 mutant in osteoblasts at the time of ovariectomy stemmed bone loss. 
Together, these data highlight roles for CaV1.2 in bone and demonstrate the potential dual anabolic 
and anticatabolic therapeutic actions of tissue-specific CaV1.2 activation in osteoblasts.
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In a previous study, increased Ca2+ influx through the TS-mutant CaV1.2 (CaV1.2
TS) channel in 
mandibular chondrocytes was shown in zebrafish and mouse models to recapitulate the macrognathia 
observed in TS patients (4). As the mandible is unique among skeletal elements in the skull to derive 
from endochondral ossification, we hypothesized that CaV1.2 may influence bone development more 
broadly. Indeed, while plasma membranes of  bone cells (e.g., osteoblasts) have not been shown to 
prominently display the voltage-dependent changes that control CaV1.2 activity in excitable tissue, 
earlier reports identified functional L-type Ca2+ channels, mainly CaV1.2, in human mesenchymal stem 
cells from BM cultured in osteogenic medium (5), in osteosarcoma cell lines (6), and in a rat osteo-
blast-like cell line (7). Further, CaV1.2 was shown in an osteosarcoma cell line to be the primary site 
for Ca2+ influx, which promoted osteoblast differentiation (8, 9). In addition, CaV1.2 expression and 
channel activity were regulated by calciotropic hormones such as 1,25(OH)2D3 (8, 10) and parathyroid 
hormone (11), suggesting a functional contribution of  CaV1.2 L-type Ca
2+ channel to bone develop-
ment. More recently, a mutation in CACNA1C causing reduced current density through CaV1.2 was 
associated with osteopenia (12).
Because CaV1.2 is a well-characterized pharmacological target, for which antagonists are widely used 
to treat hypertension, angina, and cardiac arrhythmias, we set out to explore CaV1.2 contributions to bone 
development and the consequent therapeutic potential of  modulating CaV1.2 activity in bone. We charac-
terized the expression profile of  CaV1.2 during bone development and exploited CaV1.2
TS transgenic mouse 
models to show that the gain-of-function CaV1.2
TS promotes bone formation both during development and 
postnatally. We provide evidence that the augmented bone mass results from increased osteoblast differen-
tiation and decreased osteoclast formation. With this foundation, we then demonstrated that activation of  
CaV1.2
TS expression in osteoblasts reduced bone loss in an ovariectomy-induced (OVX-induced) osteopo-
rosis mouse model.
Results
CaV1.2 is expressed during mouse bone development. To determine whether CaV1.2 contributes to bone devel-
opment, we first examined endogenous CaV1.2 expression in developing limbs by using a CaV1.2 report-
er mouse (B6.129P2-Cacna1ctm1Dgen/J, CaV1.2
+/lacZ) in which a lacZ cassette (with a nuclear localization 
signal) disrupts the Cacna1c locus. While complete KO of  Cacna1c is embryonic lethal due to inadequate 
cardiac output, CaV1.2
+/– mice are viable and fertile without obvious differences in any aspect of  develop-
ment (13) and only minor differences in morphology (4). The lacZ expression in CaV1.2
+/lacZ mice there-
by provides an accurate picture of  the temporospatial CaV1.2 expression pattern during development and 
definitive identification of  CaV1.2-expressing cells. We performed X-gal staining on frozen sections of  long 
bones from early postnatal mice (P10), in which we observed strong staining in the resting and proliferating 
chondrocytes, but we did not detect staining in the hypertrophic chondrocytes (Figure 1, A–C). Expression 
was also strong in the perichondrium/periosteum (Figure 1, A and D), and extensive staining appeared in 
the lining cells of  trabecular bones underneath the growth plate (Figure 1, A and E). At a later postnatal 
stage (P18), we also observed significant staining in the endosteum (Figure 1F). This staining pattern sug-
gested that at least some of  CaV1.2 resides in osteoblast progenitors, which we further tested by examining 
expression in primary BM stromal cells (BMSCs) isolated from adult CaV1.2
+/lacZ mice. CaV1.2 expression as 
indicated by lacZ staining in these BMSCs (Figure 1G) — along with previously reported RNA sequencing 
data showing CaV1.2 expression in osteoblasts and osteoblast progenitors (14), but not in the osteoclast 
lineage (15) — suggest important roles for CaV1.2 in skeletogenesis.
Pharmacological inhibition of  CaV1.2 channel activity decreased osteoblast differentiation. Based on the 
above expression patterns, we next asked whether Ca2+ influx through endogenous CaV1.2 affected 
osteoblast differentiation. We performed an in vitro osteogenesis assay with BMSCs in the absence and 
presence of  2 different specific L-type Ca2+ channel blockers, diltiazem and nifedipine, applied to the 
cultures 12 hours before adding differentiation media. Cells were then cultured with the channel blocker 
or their diluents throughout the differentiation process. After 14 days of  culture in osteogenic media, 
BMSCs treated with a channel blocker displayed substantially reduced mineralized nodule formation, 
as shown by von Kossa staining (Figure 1H). Quantitative PCR (qPCR) revealed that, in cells treated 
with the channel blocker, there was a marked decrease in transcripts of  several osteoblast markers, 
including Alpl, Ibsp, and Bglap (Figure 1I). Together, these data suggest that Ca2+ signaling through 
endogenous CaV1.2 regulates osteogenesis.
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Increased Ca2+ influx through CaV1.2 promotes bone formation in vivo. To explore whether Ca
2+ signaling 
through CaV1.2 in developing bone affects skeletogenesis in vivo, we exploited a transgenic mouse line in 
which a silenced TS mutant CaV1.2 Cacna1c cDNA (CaV1.2
TS) or a WT Cacna1c cDNA (CaV1.2
WT) as a con-
trol had been knocked into the Rosa26 locus (Rosa26-CaV1.2
TS and Rosa26-CaV1.2
WT, respectively). Expression 
of  these cDNAs can be activated in a tissue-specific manner upon Cre recombinase–mediated excision of  
an upstream stop codon (16). We activated CaV1.2
TS expression with Prx1-Cre targeting early mesenchymal 
stem cells (17), Col2a1-Cre targeting osteochondral progenitors (18), or Col1a1-Cre targeting more mature 
osteoblast-lineage cells (19). At 6 weeks of  age, mice in which CaV1.2
TS expression was driven by Prx1-Cre 
showed profoundly increased bone mass in the appendicular skeleton and in the skull but not the axial 
skeleton — consistent with the restricted expression pattern of  Prx1 (20) — as detected by radiography 
and μCT when compared with their Cre– control littermates (Figure 2, A, C, and E). The combined distal 
femur cortical and trabecular bone volume (BV/TV) in Prx1-Cre;CaV1.2
TS mice was increased by > 2-fold 
compared with controls at 6 weeks of  age (Figure 2D). CaV1.2
TS expression driven by either Col2a1-Cre 
or Col1a1-Cre produced an increased bone mass phenotype similar to that observed in Prx1-Cre;CaV1.2
TS 
mice (Supplemental Figure 1, A, B, D and E; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.95512DS1). Compared with the appendicular-restricted phenotype in 
the Prx1-Cre;CaV1.2
TS mice, we observed increased bone mass in both the appendicular and axial skeleton 
(data not shown) in the Col2a1-Cre;CaV1.2
TS and Col1a1-Cre;CaV1.2
TS mice, however. These results are consis-
tent with the broad expression pattern of  Col2a1-Cre and Col1a1-Cre throughout the skeleton. The high bone 
mass phenotype persisted at least to 12 months of  age (data not shown) and resulted in almost complete 
obliteration of  the BM cavity in long bones. Consistent with obliteration of  the BM cavity and predicted 
extramedullary hematopoiesis, the CaV1.2
TS mutant mice exhibited marked splenomegaly (Supplemental 
Figure 2). In contrast, mice expressing CaV1.2
WT from Rosa26 driven by these 3 Cre lines displayed no differ-
ence in bone mass compared with their Cre– littermate controls, as shown by radiography or μCT (Figure 
2B and Supplemental Figure 1, G–J). This latter observation suggests that expression of  the noninactivat-
ing CaV1.2
TS mutant channel — not just overexpression of  CaV1.2 — promotes increased bone mass in vivo. 
Alcian Blue Hematoxylin/Orange G (ABH/OG) staining confirmed that both primary and secondary ossi-
fication centers of  CaV1.2
TS mutant mice were occupied with excessive bone (Figure 2F and Supplemental 
Figure 1, C and F). Extensive Alcian Blue–stained cartilage remnant was detected in the primary spongiosa 
under the growth plate of  mutant mice (Figure 2F and Supplemental Figure 1, C and F). Moreover, the 
Figure 1. Endogenous CaV1.2 is expressed during mouse endo-
chondral ossification and in BMSCs, and pharmacological 
inhibition of CaV1.2 channel activity decreases osteoblast 
differentiation. (A) LacZ staining of CaV1.2+/lacZ femur at P10 at 
5× magnification. (B–E) Boxed regions shown in A indicate the 
presence of lacZ+ cells in the resting (B) and proliferating (C) chon-
drocytes, in the perichondrium/periosteum (D), and in the lining 
cells of trabecular bones (E). (F) LacZ staining of CaV1.2+/lacZ tibia at 
P18, showing lacZ staining in the endosteum. (G) LacZ staining of 
CaV1.2
+/lacZ BMSCs cultured for 6 days on coverslip in α-MEM (with-
out ascorbic acid) plus 15% FBS and 1% penicillin/streptomycin. 
(H) von Kossa staining of WT BMSCs after 14 days of differentia-
tion in the presence of the L-type Ca2+ channel–specific blockers 
diltiazem (10 μM) or nifedipine (10 μM), n ≥ 3. (I) Expression analy-
sis of osteoblast markers by quantitative PCR of WT BMSCs after 
9 days of differentiation in the absence and presence of diltiazem 
(10 μM). Bar values are normalized means (normalized to H2O 
group) ± SD (n = 3, **P < 0.01). Statistical analysis was performed 
by 2-tailed unpaired t test.
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mutant bones lacked sculpting (Figure 2C and Supplemental Figure 1, A and D), indicating osteoclast 
defects (see below for further analysis).
Since the Prx1-Cre driver activated CaV1.2
TS expression during skeletal development, we next assessed 
whether we were able to detect the increase in bone mass in embryonic stage. Indeed, at P0, histology con-
firmed that Prx1-Cre;CaV1.2
TS femurs possessed a thicker bone collar and higher bone mass in the presump-
tive marrow cavity compared with littermate controls (Figure 2, G and H).
Increased Ca2+ influx through CaV1.2 promotes osteoblast differentiation. To investigate further whether 
enhanced osteoblast function contributed to the increased bone mass, we performed dynamic histomor-
phometric analysis using calcein and alizarin red double labeling. Extensive green and red labeling was 
observed in the Prx1-Cre;CaV1.2
TS mutant femur, in stark contrast to that in the control, indicating more 
active bone formation in CaV1.2
TS-expressing mice (Figure 3, A and B). A similar result was observed in 
Col2a-Cre;CaV1.2
TS mutant femurs with calcein double labeling (Supplemental Figure 3, A and B).
To test the role of  CaV1.2
TS in osteogenesis directly, we performed osteoblast differentiation assays in 
vitro by isolating BMSCs from Rosa26-CaV1.2
TS adult mice and infecting the cultured cells with adenovirus 
expressing either Cre recombinase (to remove the floxed STOP codon) or GFP as a control. von Kossa 
staining revealed widespread formation of  mineralized nodules in CaV1.2
TS expressing (infected with Cre) 
BMSCs after 10 days of  differentiation, a time when there was limited mineralization in the control (infect-
ed with GFP) BMSCs (Figure 3C). We explored the mechanisms driving the accelerated mineralization 
in BMSCs expressing CaV1.2
TS with qPCR. This revealed markedly upregulated mRNA expression of  2 
master osteogenic transcription factors, Runx2 and Sp7, in CaV1.2
TS-expressing BMSCs (Cre-infected) com-
pared with control cells (GFP-infected) 48 hours after exposure to osteogenic differentiation media (Figure 
3D). The increase persisted for the ensuing 15 days. Similarly, expression of  Alpl, Ibsp, and Bglap transcripts 
was also elevated within 48 hours of  differentiation in CaV1.2
TS-expressing BMSCs and remained signifi-
cantly higher (compared with control) over the following 15 days (Figure 3D). Thus, these results indicate 
that expression of  CaV1.2
TS accelerated osteoblast differentiation of  BMSCs in vitro.
Figure 2. Expression of the CaV1.2TS channel increas-
es bone mass in vivo. (A and B) Radiographs of the 
whole bodies of 6-week-old Cre–;CaV1.2
TS (control) 
and Prx1-Cre;CaV1.2
TS (mutant) littermate mice. 
(C) μCT 3-D reconstruction images of the femurs 
of 6-week-old Cre–;CaV1.2
TS (control, Prx1-) and 
Prx1-Cre;CaV1.2
TS (mutant, Prx1+)  littermate mice. 
(D) μCT analysis of BV/TV obtained from 800 slices 
(10-μm thick; 8 mm total) from the distal femur, a 
region indicated by the dashed lines in C. Bar values 
are means ± SD (n ≥ 3, **P < 0.01). (E) μCT 3-D 
reconstruction images of skulls of 6-week-old Cre–
;CaV1.2
TS and Prx1-Cre;CaV1.2
TS littermate mice. (F) 
Alcian blue Hematoxylin/Orange G (ABH/OG) stain-
ing of longitudinal femur sections from 6-week-old 
Cre–;CaV1.2
TS and Prx1-Cre;CaV1.2
TS littermate mice 
at 1.25× magnification. Shown to the right of the 
main images are 10× magnifications of the sec-
ondary ossification center (top), primary spongiosa 
(middle), and marrow region (bottom). (G) ABH/
OG staining of longitudinal femur sections from 
Cre–;CaV1.2
TS and Prx1-Cre;CaV1.2
TS littermate mice at 
P0. (H) Analysis of bone collar thickness (B. collar 
Th) and percentage of bone area over tissue area (B. 
Ar/T. Ar) of femur diaphysis from Cre–;CaV1.2
TS and 
Prx1-Cre;CaV1.2
TS littermate mice at P0. Bar values 
are means ± SD (n = 3. **P < 0.01). Statistical analy-
sis was performed by 2-tailed unpaired t test.
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CaV1.2
TS channel blocks osteoclast differentiation. The lack of  sculpting of  CaV1.2
TS mutant long bones and 
the excessive cartilage remnant in the mutant primary spongiosa prompted us to hypothesize that osteo-
clast defects also contributed to the increased bone mass in CaV1.2
TS mutant bones. To test this hypothesis, 
we performed tartrate-resistant acid phosphatase (TRAP) staining on femurs from 6-week-old mice. We 
observed substantially fewer osteoclasts in CaV1.2
TS-expressing mice compared with littermate controls 
(Figure 4A and Supplemental Figure 3C). Quantitative analysis showed that osteoclast number per tissue 
area (Oc. N/T. Ar) was decreased by 55% and osteoclast area per tissue area (Oc. Ar/T. Ar) decreased by 
54% in Prx1-Cre;CaV1.2
TS mice (Figure 4B). A similar phenotype was also observed in Col2a1-Cre;CaV1.2
TS 
mice (Supplemental Figure 3, D and E), indicating reduced osteoclastogenesis in CaV1.2
TS mutant mice. 
As Prx1-Cre, Col2a1-Cre, and Col1a1-Cre do not target the osteoclast lineage, we hypothesize that CaV1.2
TS 
interfered with osteoblast-mediated osteoclastogenesis through the osteoprotegerin/RANKL (OPG/
RANKL) pathway. We tested this by measuring serum OPG, an inhibitor of  RANKL, and observed 
a 34% increase of  OPG in Prx1-Cre;CaV1.2
TS and a 27% increase in Col2a1-Cre;CaV1.2
TS transgenic mice 
Figure 3. CaV1.2TS channel promotes osteoblast differentiation. (A) Representative images of calcein and alizarin red double labeling in femurs from 6-week-old 
control Cre–;CaV1.2
TS and Prx1-Cre;CaV1.2
TS littermate mice. (B) Analysis of the percentage of double-labeling area over tissue area underneath the growth plate (Dl. 
Ar/T. Ar) in control Cre–;CaV1.2
TS (Ctrl) and Prx1-Cre;CaV1.2
TS (Prx1-TS) littermate mice. Bar values are means ± SD (n = 3. *P < 0.05). (C) von Kossa staining of control 
(Ad-GFP) versus CaV1.2
TS-expressing (Ad-Cre) BMSCs after 10 days of differentiation, n ≥ 3. (D) Expression analysis by quantitative PCR of control (Ad-GFP) versus 
CaV1.2
TS-expressing (Ad-Cre) BMSCs at D0 (6 hours of differentiation) or after 2, 10 and 17 days (D2, D10, and D17) of differentiation. Bar values are means ± SD (n = 
3. *P < 0.05 and **P < 0.01). Statistical analysis was performed by 2-tailed unpaired t test, and a P value less than 0.05 was considered significant.
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(Figure 4C and Supplemental Figure 3C). We further examined whether CaV1.2
TS affects the Rankl/Opg 
(Tnfs11/Tnfrsf11b) mRNA expression ratio in primary BMSC cultures after activating CaV1.2
TS expression 
and found — consistent with the in vivo data — a 61% decrease in CaV1.2
TS-expressing BMSCs (Figure 
4D). Additionally, we cocultured BM-derived macrophages (BMMs) with CaV1.2
TS-expressing or WT cal-
varial osteoblasts in the presence of  1,25-dihydroxyvitamin D3 and prostaglandin E2 and observed less 
TRAP-positive osteoclasts with osteoblasts expressing the CaV1.2
TS than with WT osteoblasts (Figure 4, E 
and F), suggesting that CaV1.2
TS expressed in cells of  osteoblast lineage blocks osteoclastogenesis.
Postnatal expression of  CaV1.2
TS channel in Sp7-lineage cells enhances accrual of  trabecular bone and prevents 
estrogen deficiency–induced bone loss. Having shown that CaV1.2
TS expression enhances bone formation, we 
tested whether we could exploit CaV1.2
TS expression to stimulate bone formation postnatally. We gener-
ated a doxycycline-inducible Sp7-Cre;CaV1.2
TS line by crossing the floxed-STOP Rosa26-CaV1.2
TS with an 
inducible Sp7-Cre recombinase (Sp7-tTA;TetO-EGFP-Cre) (21). We blocked Cre expression with doxycy-
cline-impregnated food until mice were 2 months old, then we removed doxycycline to activate CaV1.2
TS 
and analyzed the long bones 8 weeks later. μCT 3-D reconstruction of  the distal femur metaphysis revealed 
a marked increase in trabecular bone in CaV1.2
TS-expressing mice (Supplemental Figure 4A). Quantitative 
measurement showed that BV/TV was increased by 56% in Sp7-Cre;CaV1.2
TS male mice after activating 
CaV1.2
TS expression for 8 weeks. This increase in bone acquisition was characterized by significant increase 
in trabecular thickness (Tb.Th) and trabecular number (Tb.N), whereas trabecular bone separation (Tb.Sp) 
was unaffected (Supplemental Figure 4B).
We then tested whether expression of CaV1.2
TS in postnatal bone could prevent estrogen deficiency–induced 
bone loss in female mice. We performed OVX on 2-month-old Sp7-Cre;CaV1.2
TS mice or their Cre–;CaV1.2
TS litter-
mate controls and induced CaV1.2
TS expression by removing doxycycline at the time of surgery. Simultaneous 
sham operation on the control (Cre–;CaV1.2
TS littermates) allowed us to monitor the effects of OVX in the absence 
of activating CaV1.2
TS. At 4 months old, the growth plates of the distal femur and the length of the humerus were 
Figure 4. CaV1.2TS channel decreases osteoclast differentiation. (A) Representative images of TRAP staining in femur sections from 6-week-old control 
(Cre–;CaV1.2
TS) and Prx1-Cre;CaV1.2
TS littermate mice. (B) Analysis of osteoclast number (Oc. N) or osteoclast area (Oc. Ar) over tissue area (T. Ar) underneath 
the growth plate. Bar values are means ± SD (n ≥ 6. **P < 0.01). (C) Serum OPG levels of control Cre–;CaV1.2TS and Prx1-Cre;CaV1.2TS littermate mice at 6 
weeks old. Bar values are means ± SD (n = 7. **P < 0.01). (D) Expression analysis of Rankl/Opg mRNA ratio by qPCR of control (Ad-GFP) versus CaV1.2TS-ex-
pressing (Ad-Cre) BMSCs after 8 days (D8) of differentiation. Bar values are means ± SD (n = 3. *P < 0.05). (E) Representative images of TRAP-stained 
cells in cocultures of BMMs and control (Cre–;CaV1.2
TS) or CaV1.2
TS-expressing (Sp7-Cre;CaV1.2
TS) calvarial osteoblasts in the presence of 10 nM 1,25-dihy-
droxyvitamin D3 and 1 μm prostaglandin E2, n = 3. (F) Analysis of the number of TRAP-positive cells per well. Bar values are means ± SD (n ≥ 10. **P < 0.01). 
Statistical analysis was performed by 2-tailed unpaired t test, and a P value less than 0.05 was considered significant.
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normal in these mice (Supplemental Figure 5), sug-
gesting that depleting estrogen or activating CaV1.2
TS 
expression at the 2-month-old time point does not 
affect the growth plate and the longitudinal growth 
of long bones. In the Cre– controls subject to OVX, 
we observed noticeable trabecular bone loss (com-
pared with sham controls) 8 weeks after OVX (Fig-
ure 5A). Quantitative measurements showed that 
43% of BV/TV was lost in control mice after OVX 
(Figure 5B), consistent with less trabecular bones 
shown in H&E staining (Figure 5C). Compared with 
sham-operated control mice, the parameter Tb.Th 
remained relatively constant in OVX mice through-
out the 8-week experimental period, while Tb.N 
decreased and Tb.Sp increased after OVX surgery 
(Figure 5B), indicating that OVX can induce loss of  
trabecular bone by perforation and division, as seen 
in previous OVX experiments (22, 23). Dynamic 
histomorphometric analysis showed that bone formation rate (BFR) was decreased by 71%, mineral apposition 
rate (MAR) was decreased by 49%, and the percentage of mineralizing surface over bone surface (MS/BS) was 
decreased by 38% in the control group after OVX (Figure 5, D and E), indicating reduced osteoblast function 
after estrogen deficiency at 2 months of age. In contrast, activation of CaV1.2
TS (by removing doxycycline) at the 
time of surgery effectively mitigated bone loss and maintained bone mass after OVX (BV/TV, 4.25% ± 0.54%) 
to the same level as that in the sham-operated controls (BV/TV, 4.49% ± 0.33%) (Figure 5, A and B). The preser-
vation of bone mass in activated CaV1.2
TS mice after OVX was accompanied by maintenance of Tb.N and Tb.Sp 
compared with control sham mice (Figure 5B). Consistent with these data, we confirmed by H&E staining that 
OVX CaV1.2
TS mice maintained trabecular bone in femurs similar to control sham mice and stemmed trabecu-
lar bone loss compared with OVX control mice (Figure 5C). The maintenance of bone mass after OVX in the 
CaV1.2
TS-expressing bones was in part due to sustained osteoblast function, as dynamic histomorphometric anal-
ysis showed that BFR, MAR, and MS/BS were unaffected in CaV1.2
TS mutant femurs after OVX compared with 
control sham mice and were significantly higher than control OVX mice (Figure 5, D and E).
Figure 5. CaV1.2TS prevents estrogen deficiency–
induced bone loss. (A) μCT 3-D reconstruction images 
of metaphyses of distal femurs of mice 8 weeks after 
sham surgery, ovariectomy [OVX], and OVX with CaV1.2
TS 
expression (Sp7-Cre;CaV1.2
TS). (B) Analysis of bone 
volume density (BV/TV), trabecular thickness (Tb.Th), 
trabecular number (Tb.N), and trabecular spacing (Tb.
Sp) of metaphyses of distal femurs of mice 8 weeks 
after sham surgery, OVX, or OVX with CaV1.2
TS expres-
sion (Sp7-Cre+;CaV1.2
TS). Bar values are means ± SD (n ≥ 
8. **P < 0.01). (C) H&E staining of mice 8 weeks after 
sham surgery, OVX, or OVX with CaV1.2
TS expression 
(Sp7-Cre;CaV1.2
TS). (D) Representative images of calcein 
and alizarin red double labeling in the trabecular bones 
underneath the growth plate of mice 8 weeks after 
sham surgery, OVX, or OVX with CaV1.2
TS expression 
(Sp7-Cre;CaV1.2
TS). (E) Dynamic histomorphometry anal-
ysis of trabecular bones 1.5 mm away from the growth 
plate of mice 8 weeks after sham surgery, OVX, or OVX 
with CaV1.2
TS expression (Sp7-Cre;CaV1.2
TS). BFR, bone 
formation rate; MAR, mineral apposite rate; and MS/BS, 
percentage of mineralizing surface over bone surface. 
Bar values are means ± SD (n ≥ 8. *P < 0.05 and **P < 
0.01). Statistical analysis was performed by one-way 
ANOVA followed by Tukey’s post-test analysis, and a P 
value less than 0.05 was considered significant.
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Discussion
This study revealed unexpected roles for the CaV1.2 voltage–gated Ca
2+ channel in bone development and 
remodeling and uncovered consequences of  increased Ca2+ influx through the channels. Using conditional 
mouse models and the BMSC culture system, we demonstrated that expression of  a transgenic CaV1.2
TS 
mutant channel promotes bone formation and inhibits bone resorption during skeletal development, 
homeostasis, and osteoporotic contexts. Actions of  voltage-gated L-type Ca2+ channels were previously 
reported in osteosarcoma cell lines (6, 8, 24), and a previous immunohistochemical study suggested the 
presence of  CaV1.2 in developing bones (25). Our data, exploiting a definitive CaV1.2 signal from a mouse 
in which lacZ was knocked into the Cacna1c gene, reveal the endogenous CaV1.2 expression pattern and 
avoid nonspecific signals that can arise from detection by antibodies. With this approach, we observed 
prominent endogenous CaV1.2 expression in the developing perichondrium/periosteum, endosteum, and 
growth plate, which all give rise to osteoprogenitors. We did not detect CaV1.2 in the marrow cavity, as was 
suggested by one study using an immunohistochemical approach (25) but not by another (26). Further, we 
observed the consequences of  activating CaV1.2
TS expression in vivo. Thus, these data extend previous find-
ings for a CaV1.2 role in mandibular development (4) and highlight additional unexpected roles for CaV1.2 
Ca2+ channels in nonexcitable tissue.
It is intriguing that, in the growth plate, we observed CaV1.2 expression in the proliferating chondro-
cytes but not hypertrophic chondrocytes. One resulting hypothesis is that termination of  CaV1.2 expres-
sion (and the resulting downstream Ca2+ signaling) is required for the transition of  proliferating chon-
drocytes to a hypertrophic state. Consistent with this hypothesis is our observation that bones expressing 
CaV1.2
TS are shorter: in CaV1.2
TS-expressing mice in which CaV1.2
TS was driven by Prx1-Cre or Col2a1-Cre 
— both of  which target chondrocyte lineages — a delay in chondrocyte maturation may reduce the ulti-
mate length of  the long bones.
Because these mouse models all employed Cre recombinases that drove CaV1.2
TS expression in osteo-
blast lineages, and not in osteoclasts or their precursors, we conclude that the observed anticatabolic 
responses resulted from an increase in the Rankl/Opg expression ratio and OPG secretion and consequent 
extrinsic inhibition of  osteoclastogenesis. This is consistent with previous data showing that CaV1.2 regu-
lates OPG secretion (27) and the well-defined roles for CaV1.2 channels in promoting hormone secretion 
from endocrine tissue. Moreover, our lacZ expression data showed that CaV1.2 is expressed within bone 
tissue where osteoblast precursor cells reside, and previous RNA-seq data showed no expression of  CaV1.2 
in murine BMMs or during osteoclast differentiation (15).
Our data showing upregulation of  2 master osteogenic transcription factors, Runx2 and Sp7, after 
expression of  CaV1.2
TS suggest that increased Ca2+ influx through the noninactivating mutant CaV1.2 chan-
nel augments signaling cascades that promote osteoblast differentiation and mineralization. Moreover, the 
reduced mineralization observed in BMSC cultures treated with CaV1.2 blockers highlights the physiolog-
ic contribution of  Ca2+ influx through endogenous CaV1.2 channels in osteoblast precursors. Neverthe-
less, we cannot exclude the possibility that Ca2+-independent signaling through CaV1.2
TS contributes to 
the CaV1.2
TS-induced increase in bone formation. Two previous studies reported that the mutant CaV1.2
TS 
channel activates Ca2+-independent downstream signaling pathways in neurons or hair follicles, as suggest-
ed by experiments showing that expression of  a “pore-dead” CaV1.2
TS channel recapitulated the CaV1.2
TS 
channel effects (28, 29). Based on observations regarding the role of  CaV1.2 in mandibular development 
— in which a Ca2+-permeant WT or CaV1.2
TS mutant channel, but not a pore-dead channel, successfully 
rescued abnormal development after CaV1.2 knockdown — we propose that Ca
2+ influx through CaV1.2 is 
essential for bone development.
Our data showing that activating a transgenic, overexpressed CaV1.2
TS channel during embryogenesis or 
postnatally increases bone mass and prevents bone loss secondary to estrogen deficiency do not likely have 
implications for TS patients, who have a mutant, endogenous CACNA1C locus present throughout develop-
ment and beyond. Rather, the consistent results obtained by activating a CaV1.2
TS channel specifically with 
Prx1-Cre, Col2a1-Cre, or Col1a1-Cre suggest that increasing Ca2+ influx through a noninactivating CaV1.2 chan-
nel in any osteoblast lineage cell promotes bone formation by increasing osteoblast differentiation and inhib-
iting osteoclast differentiation. The dual effect of  transgenic CaV1.2
TS suggests a possible therapeutic strategy 
for osteoporotic or osteopenic conditions. The majority of  current osteoporosis treatments are anticatabolic 
agents that reduce osteoclast bone resorption, such as estrogens, bisphosphates, and calcitonin (30, 31). These 
anticatabolics (especially bisphosphonates) are associated with gastrointestinal problems, osteonecrosis of  
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the jaw, and atypical femur fractures or fragility fractures. Therefore, our approach here is more in line with 
anabolic therapies such as recombinant human parathyroid hormone (rhPTH) (32) and more recently devel-
oped agents demonstrating dual roles (e.g., romosozumab) that show increasing promise (33). Further, the 
increased bone accrual postnatally observed with the inducible Sp7-Cre model highlights the potential for the 
development of  bone-targeted CaV1.2 agonists, starting with lead compounds such as BayK-8644 or FPL 
64176, for anabolic and anticatabolic skeletal effects, as observed in our CaV1.2
TS mice.
Methods
Experimental mouse models. CaV1.2
+/LacZ, Rosa26-CaV1.2
TS, and Rosa26-CaV1.2
WT mouse lines have been 
described previously (4, 16). Homozygous Rosa26-CaV1.2
TS or Rosa26-CaV1.2
WT mice were crossed with the 
transgenic Prx1-Cre (17), Col2a1-Cre (18), or 2.3Col1a1-Cre (19) mice. All skeletal analyses were performed 
on 6-week-old mice unless otherwise specified. For serum OPG assay (R&D Systems), serum was collected 
from 6-week-old mice without fasting following the manufacturer’s instructions.
To generate inducible mouse models for investigating postnatal bone formation and remodeling, we 
crossed Rosa26-CaV1.2
TS mice with Sp7-Cre (B6.Cg-Tg [Sp7-tTA, tetO-EGFP/cre] 1Amc/J; The Jackson Lab-
oratory) (21). Breeders and their pups were maintained on a rodent diet containing 625 mg/kg doxycycline 
(Harlan) to suppress Cre recombinase expression in the embryonic and early postnatal stages. Chow was 
replaced with regular rodent diet (no doxycycline) to induce Cre expression when mice were 2 months old. For 
OVX experiments, OVX or sham operation were performed on 2-month-old female mutant (Sp7-Cre;CaV1.2
TS) 
and control (Cre–;CaV1.2
TS) mice under isofluorane anesthesia. The doxycycline diet was replaced with regular 
rodent diet on the same day of  OVX or sham surgery. Tissue was collected for analysis 8 weeks after OVX.
Chemicals. All chemicals were obtained from MilliporeSigma unless otherwise indicated.
X-gal staining. X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) staining was performed on 
frozen tissue sections. Forelimbs or hindlimbs were fixed in 4% paraformaldehyde on ice for 20 minutes 
(embryos) or 1 hour (postnatal stage), decalcified with 14% EDTA at 4°C, processed to 30% sucrose, and 
snap-frozen embedded with OCT compound (Sakura Finetek). Frozen sections (10 μm–thick) were refixed 
in ice-cold 1× PBS with 2% paraformaldehyde, 0.2% glutaraldehyde, 2 mM MgCl2, 0.2% Tween-20, and 
30% sucrose for 10 minutes and stained with X-gal staining solution (5 mM potassium ferrocyanide, 5 mM 
potassium ferricyanide, 1 mg/ml X-gal, 2 mM MgCl2, 0.1% sodium deoxycholate, and 0.2% IGEPAL 
CA-630 in dark for 24–48 hours at 37°C. Specimens were counterstained with Nuclear Fast Red. For X-gal 
staining on BMSCs, the staining was performed for 48 hours at 37°C.
X-ray radiography and μCT analysis of  mice. X-ray radiographic images of  the hindlimbs were acquired 
using a Faxitron X-ray system (Faxitron Bioptics) at 31 kV for 9 seconds. For μCT scanning, the specimens 
were fixed in 10% neutral buffered formalin and then fitted in a 50 ml centrifuge tube with 70% ethanol. 
Images were obtained with a Scanco VivaCT 80 scanner (Scanco Medical AG) set to 55 kVp and 145 μA, 
voxel size 10.4 μm. To quantify trabecular bone parameters, 50 μCT slices (~0.5 mm total) immediately 
below the distal growth plate of  the femur were analyzed.
Double labeling and cryosectioning. For dynamic histomorphometry, mice were injected i.p. with cal-
cein and alizarin-3-methyliminodiacetic acid (MilliporeSigma) at 20 mg/kg and 40 mg/kg, respective-
ly, on days 8 and 2 prior to euthanasia. Femurs were extracted and fixed in 10% neutral buffered for-
malin for 24 hours. After washing with 1× PBS, nondecalcified femurs were processed to 30% sucrose 
and OCT embedding, and they were sectioned at 10 μm using Leica Cryostat equipped with Cryojane 
(Leica). The slides were counterstained with DAPI. Dynamic histomorphometry was performed with 
OsteoMeasure commercial software.
Histology and TRAP staining. For histology, decalcified samples were processed for paraffin embedding 
and then sectioned at 6-μm thickness. H&E, ABH/OG, and TRAP staining were performed following 
standard protocols.
Mouse BMSC isolation and culture, viral infection, and osteoblast differentiation. BMSCs were isolated asep-
tically from the femurs and tibias of  6- to 10-week-old Rosa26-CaV1.2
TS or WT mice and were plated in 
α-MEM without ascorbic acid (Thermo Fisher Scientific) with 15% FBS (Hyclone) and 1% penicillin/
streptomycin (Invitrogen) at 37°C in a 5% CO2 humidified incubator. After 48 hours of  adhesion, the media 
was changed to remove nonadherent cells. BMSCs reached confluency after an additional 4 days of  culture 
with a single media change. Cells were passaged with 0.25% trypsin-EDTA digestion (Invitrogen) and 
reseeded at 3 × 105 cells/6-well or 1 × 105 cells/12-well for mineralization assays.
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For viral infections, cells at 70% confluency were infected with adenovirus expressing either GFP or 
Cre-recombinase (Baylor College of  Medicine, Houston, Texas, USA) at a multiplicity of  infection (MOI) 
of  50 in serum-containing medium for 24 hours. Seventy-two hours after viral infection, BMSCs were cul-
tured in osteogenic media (α-MEM containing 15% FBS, 1% penicillin/streptomycin, 50 μg/ml L-ascorbic 
acid [MilliporeSigma] and 10 mM β-glycerophosphate [MilliporeSigma]). For von Kossa staining, cells 
were fixed in methanol on ice for 20 minutes, rinsed with distilled water, and exposed to 365 nm ultraviolet 
light in 5% silver nitrate solution (MilliporeSigma) for 2 minutes.
Coculture osteoclastogenesis assay. Primary calvarial osteoblasts were isolated from P0 to P2 Cre–;CaV1.2
TS 
(control) or Sp7-Cre;CaV1.2
TS pups. The calvaria were digested in 1× PBS containing 0.18% collagenase P 
(Roche Diagnostics) for 10 minutes at 37°C with vigorous shaking. The digestion was repeated 4 times, 
and the cells isolated from the last 3 digestions were combined. The isolated osteoblasts (5 × 103 cells/well) 
were seeded in a 96-well plate with 200 μl of  α-MEM containing 15% FBS and 1% penicillin/streptomycin 
in 5% CO2 at 37°C 2 days before starting the coculture. Twenty-four hours after adhesion, the medium was 
changed to osteogenic media. BMMs were isolated from BM of  WT C57BL/6J mice and cultured on a 
100-mm culture dish after lysis of  the RBC with α-MEM containing 15% FBS, 1% penicillin/streptomycin, 
and 5 ng/ml of  M-CSF for 24 hours. Nonadherent cells were collected, washed once with 1× PBS, resus-
pended in osteogenic media with addition of  10 nM of  1,25-dihydroxyvitamin D3 and 1 μm of  prostaglan-
din E2, and added to the wells of  the 96-well plate containing the calvarial osteoblasts. The coculture was 
observed for 6–9 days, and half  of  the media was changed every other day until the appearance of  giant 
osteoclasts. To visualize osteoclasts, cells were fixed and processed for TRAP staining.
Real-time PCR. Total RNA was isolated from BMSCs using RNAeasy mini kit (Qiagen). Total RNA (1 
μg) was reverse transcribed to cDNA using iScript Reverse Transcription Supermix (Bio-Rad). qPCR was per-
formed using SYBR green Supermix (Bio-Rad). Gene expression was first normalized to GAPDH and then 
normalized to control samples. The primers for Runx2, Sp7, Alpl, Bglap, and Ibsp were previously described 
(34). The primers for Gapdh are: forward, 5′ - AGTAACACCACGGAGGGGG - 3′; reverse, 5′ - GGTCT-
GATCACAGGGCATGG - 3′. The primers for Opg (Tnfrsf11b) are: forward, 5′ - CCGAGGACCACAAT-
GAACAAGT - 3′; reverse, 5′ - CTGGGTTGTCCATTCAATGATG - 3′. The primers for Rankl (Tnfs11) are: 
forward, 5′ - CTGGGCCAAGATCTCTAACATGA - 3′; reverse, 5′ - GGTACGCTTCCCGATGTTTC - 3′.
Statistics. Statistical analyses were performed using GraphPad Prism 7.0. Two-tailed unpaired t tests were 
used for 2 conditions, and 1-way ANOVA with Tukey’s post-test analysis was applied for multipe comparisons. P 
< 0.05 was considered statically significant. Data are represented as mean ± SD from n ≥ 3 experiments. qPCR 
assays were performed with 3 independent RNA isolates. Viral transfections were repeated n ≥ 3. Fold changes 
were calculated by dividing the value of the treatment group by the value of the control group at the same time 
point. Increasing or decreasing percentage changes were calculated by dividing the value of difference between 
the treatment group and control group by the value of the control group and then multiplying 100.
Study approval. All mouse protocols were approved by the IACUC at Duke University.
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